

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

OVSAHO

RRID:CVCL_3114

Type: Cell Line

Proper Citation

RRID:CVCL_3114

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3114

Proper Citation: RRID:CVCL_3114

Description: Cell line OVSAHO is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:9328139](#), [PMID:11121861](#), [PMID:15677628](#), [PMID:17671176](#), [PMID:22460905](#), [PMID:23839242](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27561551](#), [PMID:28196595](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:32612269](#), [PMID:35918200](#)

Comments: Population: Japanese., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OVSAHO

Cross References: BTO:BTO_0003502, EFO:EFO_0006727, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, BioSample:SAMN03472860, BioSample:SAMN10988236, cancercellines:CVCL_3114, Cell_Model_Passport:SIDM01377, CGH-DB:334-2, DepMap:ACH-000409, EGA:EGAS00001000610, GEO:GSM459648, GEO:GSM659398, GEO:GSM887489, GEO:GSM888571, IARC_TP53:28252, JCRB:JCRB1046, JCRB:NIHS0299,

JCRB:NIHS0341, LiGeA:CCLE_754, Millipore:SCC294,
PharmacoDB:OVSAHO_1227_2019, PRIDE:PXD003105, PRIDE:PXD003668,
Progenetix:CVCL_3114, Wikidata:Q54937035

ID: CVCL_3114

Record Creation Time: 20220427T221403+0000

Record Last Update: 20260829T235528+0000

Ratings and Alerts

No rating or validation information has been found for OVSAHO.

Warning: Discontinued: JCRB; NIHS0341

Population: Japanese., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). **Warning:** Discontinued: JCRB; NIHS0299

Population: Japanese., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 28 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Vuong TT, et al. (2026) DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment. Cancer research communications, 6(7), 1721.

Pradhan B, et al. (2026) Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer. Cancer research, 86(4), 1073.

Zhang X, et al. (2026) Targeting ZDHHC12-mediated PARP1 palmitoylation potentiates PARP inhibitor cytotoxicity. Cell reports, 45(2), 116910.

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. Advanced biology, 10(3), e00404.

Resch V, et al. (2026) Targeting Steroid-Metabolizing Enzymes with 15 β -Substituted Estrone Analogues: Dual Discovery of AKR1C2/17 β -HSD1 Inhibitors and a Fluorescent 17 β -HSD1 Ligand. Cancers, 18(12).

Littler S, et al. (2025) Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC. *iScience*, 28(6), 112555.

Garcia GL, et al. (2025) Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation. *Cancer discovery*, 15(6), 1203.

Gudoityte G, et al. (2025) Systematic profiling of cancer-fibroblast interactions reveals drug combinations in ovarian cancer. *Molecular oncology*, 19(9), 2574.

Plesselova S, et al. (2025) Recapitulating physiologically relevant oxygen levels and extracellular matrix remodeling in patient-derived tumor-immune tunable models reveal targeting opportunities for immunologically cold high-grade serous tumors. *bioRxiv : the preprint server for biology*.

Ma J, et al. (2025) P-cadherin mechanoactivates tumor-mesothelium metabolic coupling to promote ovarian cancer metastasis. *Cell reports*, 44(1), 115096.

Sottnik JL, et al. (2024) WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers. *Cancer research communications*, 4(1), 134.

Frisbie L, et al. (2024) Carcinoma-associated mesenchymal stem cells promote ovarian cancer heterogeneity and metastasis through mitochondrial transfer. *Cell reports*, 43(8), 114551.

Wang W, et al. (2024) Targeting Ovarian Cancer Stem Cells by Dual Inhibition of the Long Noncoding RNA HOTAIR and Lysine Methyltransferase EZH2. *Molecular cancer therapeutics*, 23(11), 1666.

Xu Y, et al. (2023) Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. *Cell reports*, 42(10), 113307.

Liu H, et al. (2022) KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. *Cancer immunology research*, 10(8), 1028.

Parente-Pereira AC, et al. (2022) Generation and application of TGF β -educated human V β 9V α 2 T cells. *STAR protocols*, 3(2), 101319.

Jia Y, et al. (2021) Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells. *Frontiers in oncology*, 11, 812264.

Beatson RE, et al. (2021) TGF- β 1 potentiates V β 9V α 2 T cell adoptive immunotherapy of cancer. *Cell reports. Medicine*, 2(12), 100473.

Xu H, et al. (2021) CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. *Cell reports. Medicine*, 2(9), 100394.

Gonzalez VD, et al. (2021) High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment. *Cell reports*, 36(9), 109632.